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Species A Rotaviruses (RVA) remain a leading cause of mortality in children under 5 years
of age. Current treatment options are limited. We assessed the efficacy of two VP6-specific
llama-derived heavy chain antibody fragments (VHH) -2KD1 and 3B2- as an oral prophylac-
tic and therapeutic treatment against RVA-induced diarrhea in a neonatal mouse model
inoculated with virulent murine RVA (ECw, G16P[16]I7). Joint therapeutic administration of
2KD1+3B2 (200 μg/dose) successfully reduced diarrhea duration, RVA infection severity
and virus shedding in feces. While the same dose of 2KD1 or 3B2 (200 μg) significantly
reduced duration of RVA-induced diarrhea, 2KD1 was more effective in diminishing the
severity of intestinal infection and RVA shedding in feces, perhaps because 2KD1 pre-
sented higher binding affinity for RVA particles than 3B2. Neither prophylactic nor therapeu-
tic administration of the VHH interfered with the host’s humoral immune response against
RVA. When 2KD1 (200 μg) was administered after diarrhea development, it also signifi-
cantly reduced RVA intestinal infection and fecal shedding. Host antibody responses
against the oral VHH treatment were not detected, nor did viral escape mutants. Our find-
ings show that oral administration of anti-VP6 VHH constitute, not only an effective prophy-
lactic treatment against RVA-associated diarrhea, but also a safe therapeutic tool against
RVA infection, even once diarrhea is present. Anti-VP6 VHH could be used complementary
to ongoing vaccination, especially in populations that have shown lower immunization effi-
cacy. These VHH could also be scaled-up to develop pediatric medication or functional
food like infant milk formulas that might help treat RVA diarrhea.
Introduction
Species A rotaviruses (RVA) remain a leading cause of child mortality, causing around 215,000
deaths of<5 y old children in 2013, mainly in developing countries [1]. Ongoing clinical man-
agement of RVA-associated diarrhea is non-specific and mainly based on preventing the symp-
toms and dehydration through the administration of Oral Rehydration Salts (ORS), zinc
supplementation and continued feeding [2]. Several non-specific therapies have been tested,
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including the use of different probiotics [3–5], drugs such as nitazoxanide [6], strict sanitation
and hand hygiene—with limited benefits—[7] and herbal compounds used in folk medicine
for the treatment of diarrhea [8,9]. Several attempts to develop a RVA-specific passive immune
treatments have been made, including breast-feeding promotion [10], administration of RVA-
specific bovine colostrum [11], egg yolk polyclonal IgY antibodies (Abs) to RVA [12–14] and
RVA-specific monoclonal Abs [15,16]. Immune bovine colostrum was demonstrated to signifi-
cantly reduce the risk of RVA gastroenteritis in children during an outbreak and the number of
days with RVA-associated diarrhea [17]. On the other hand, IgY egg yolk immunoglobulins
derived from hyperimmunized hens were shown to confer protection against RVA-associated
diarrhea in gnotobiotic piglets [14] and a reduction of stool output in children spending short
periods in hospitals [12,18,19]. However, none of these remedies is available as a commercial
preparation, probably due to potentially adverse effects concerning the risk of allergic reactions
and contamination with adventitious viruses [10,19]. Monoclonal Abs (mAbs) to RVA have
been only tested prophylactically in the suckling mouse model for simian RVA (RRV strain)
infection in which mouse pups were successfully protected against RVA infection and diarrhea
when administered thirty minutes before infection [15,16]. However, up to now, this passive
immune strategy has not been implemented as a treatment for RVA-associated diarrhea.
While Abs can have high specificity, the doses required to treat patients are typically large [20].
Also, conventional mAbs face denaturation because of the stomach’s acidic pH and degrada-
tion by proteases in the stomach and intestine into small peptides or amino acids which are
subsequently absorbed [21].
All camelid species possess a functional class of Abs devoid of light chains, referred to as
heavy-chain Abs [22], whose single N-terminal variable domain (VHH or nanobody1) binds
antigen without requiring domain pairing [23]. VHH consist of only one polypeptide chain
and are expressed to a high level in microorganisms [24,25], mammalian cell lines, insect larvae
[26] and plants [27,28] with low production costs [29], which represents an advantage for their
application in massive treatment strategies. In the present work, we investigated llama-derived
single-chain Ab fragments -VHH- directed to VP6 as a treatment against RVA-associated
disease.
RVA have a genome consisting of 11 segments of double-stranded RNA that mainly encode
a single polypeptide, allowing the virus to express six structural proteins (VPs) and five non-
structural proteins (NSPs) [30]. RVA infections induce neutralizing Abs against outer capsid
proteins VP4 and VP7 [31]. Upon primary infection these neutralizing Abs are mainly serotype
specific and can hence protect against homosubtypic infections [32]. The inner capsid is com-
posed of VP6 proteins which are vastly conserved, highly immunogenic and constitute the tar-
get antigen of most immunodiagnostic tests [33]. VP6 is not a target for conventional
neutralizing Abs [34,35], although VP6-specific IgA mAbs were shown to induce intracellular
viral inactivation during transcytosis as a mechanism of host defense against RVA infection in
a “backpack model” in BALB/c mice [34]. Previous studies showed that VHH directed to VP6
are able to neutralize a wide range of RVA strains [36,37], suggesting that the conserved nature
of this protein allows for cross-targeting of RVA strains.
VHH have a molecular weight of only 12–15 kDa rather than the 150 kDa of conventional
Abs, and their more compact architecture allows them to access hidden targets [29] inaccessi-
ble to conventional Abs. They can resist temperatures above 90°C [38] and have a chemical sta-
bility of 60 kJ/mol−1 [39,40]. VHH are also resistant to other denaturing conditions, such as
extreme pH [23,39] and high urea concentrations [41]. All these features encourage the use of
VHH in oral therapies. VHH present high stability and therefore can be incubated for up to
200 hours at 37°C [42] or maintained for months at 4°C [29] without losing antigen-binding
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capacity. Particularly, lyophilized anti-RVA VHH together with rice water could be stored for
a year at room temperature without losing their neutralizing activity against RVA [43].
Up to now, two independent VHH libraries to RVA have been generated from immunized
llamas [44,45]. Van der Vaart and coworkers developed a library using the complete RVA
virion from the simian RRV strain G3P[3]I2 (including clones ARP1 and ARP3) while Garai-
coechea et al. used recombinant VP6 from bovine C486 strain G6P[1]I2 (including clones
2KD1 and 3B2) [37,44]. In both cases, VHH recognized RVA intermediate layer VP6 even
though the exact epitopes have not yet been elucidated [37,45].
Some of these VHH also showed virus neutralization activity in vivo against different strains
of RVA. In several previous studies, Lactobacillus paracasei that expressed anchored anti-RVA
VHH clones ARP1 and/or ARP3 were constructed, aiming at obtaining a synergy between the
effects of probiotics on diarrhea and the specific properties of ARP1/ARP3 against RVA [46–
48]. ARP1 was also used to create an anti-RVA product by engineering rice plants to express
the VHH (MucoRice-ARP1) which could be used as rice powder or rice water [43]. Both for-
mulations achieved a significant reduction of diarrhea duration and disease severity in the neo-
natal mouse model for simian RRV infection when administered both before and shortly after
viral inoculation [43,46–48]. More recently, ARP1 was tested in a clinical trial involving infants
with RVA-associated diarrhea in Bangladesh where it successfully reduced the stool output but
did not modify the duration of the diarrhea or the viral shedding [49].
Regarding VHH developed by our group, administration of clone 3B2 successfully pre-
vented the occurrence of RVA-induced diarrhea in the gnotobiotic pig model for human RVA
infection [36]. Both 2KD1 and 3B2 clones have been administered to neonatal mice before
infection with murine RVA, and each of them conferred partial protection against diarrhea
and significantly reduced virus shedding [37]. The therapeutic treatment of RVA-associated
diarrhea using VHH Abs has never been systematically addressed. Moreover, little is known
about the usefulness of VP6-specific VHH Abs as a treatment to RVA once virus infection has
already induced diarrhea.
Here, we present the biological properties of VHH 2KD1 and 3B2 for prophylactic and
post-infection therapeutic treatment of RVA in a neonatal mouse model with an extended time
frame and sequential sampling that allowed us a more thorough exploration of how these
VHH impair the development of RVA infection and disease. We also addressed concerns
about the possible development of a host’s anti-VHH immune response upon treatment with
VHH, a potential interference of the treatment with the host’s immune response against RVA,
and the potential emergence of viral VP6 escape mutants due to the treatment.
Materials and Methods
Anti-VP6 VHH production
Anti-RVA VHH 2KD1 and 3B2 were obtained from an immune library of a llama immunized
with recombinant inner capsid protein VP6 (from bovine RVA C486 strain G6P[1]I2), as pre-
viously described [37]. Both clones’ sequences are available at GenBank with the following
accession numbers: JC36618 (2KD1), JC036616 (3B2). For this study, cDNA from both clones
were re cloned using the restriction enzymes NcoI and NotI into the expression vector pHEN6.
Escherichia coli XL-1 Blue were freshly transformed with the plasmid constructs. Both VHH
clones were later purified from the periplasmic extract using a High-Trap HP Ni-chelating col-
umn (Amersham Biosciences) as previously described [37]. Purity of the VHH was assessed by
Coomassie Blue staining of SDS-PAGE in which no significant contamination was observed
(S1 Fig). Both VHH were then re suspended in commercial sterile saline solution (NaCl 0.9%
p/v, pH 7.3) in a concentration of 3.9 mg/ml for 2KD1 and 7.29 mg/ml for 3B2, according to
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Nanodrop measures. These values were equivalent to an Ab titer of 32,768 (11.90 ng) and
65,536 (11.12 ng) respectively when tittered in an ELISA that measures VHH titers against
RVA VP6, as described below in “Determination of VHH binding specificity” section, indicat-
ing that the molecules were expressed not only with good yield (mean value of 9.2 mg/L of cul-
ture) but also with optimal functionality.
Virus
Neonatal BALB/c mice were infected with murine RVA strain ECw (G16P[16]I7) kindly pro-
vided by Dr. Alejandro Castello, Quilmes University with the permission of Ninguo Feng and
Harry Greenberg. Mice were euthanized at Post Inoculation Day (PID) 4 and the intestinal
contents were filtered and diluted in minimal essential medium (MEM; Invitrogen). The viral
infectivity titer was determined by Cell Culture Immunofluorescence (CCIF) assay and
expressed in Focus Forming Units (FFU)/ml). For viral inoculation of neonatal mice we used a
volume of 100 μl, containing a total of 1778 times the dose that caused diarrhea in 50% of the
suckling mice (DD50) equivalent to 10
3 FFU. Murine ECw RVA attenuated by multiple cell cul-
ture passage was propagated in MA-104 cells (104 FFU/ml) and used in Enzyme-Linked
ImmunoSorbent Assays (ELISA) and CCIF assays.
Animals
BALB/c mice were purchased from the breeding facilities at the Veterinary College, La Plata
University and mated to produce offspring under regulated conditions. Pregnant dams were
housed individually and normal pellet diet and water were provided ad libitum. In order to
improve the housing conditions of the dams and their litters, we provided cotton balls for nest-
ing purposes and sunflower seeds to enrich the protein content of the normal pellet diet. Neo-
natal mice were euthanized by manual beheading and adult mice by cervical dislocation after
mild sedation with Isoflurane (inhalation for 30 seconds). Prior to the experiments, a protocol
was established for early/humane endpoints for animals that presented severe illness before the
experimental endpoint. Mice pups were euthanized if they presented severe lesions caused by
improper intragastrical administration of the treatment or if they showed signs of severe dehy-
dration, generally caused by a combination of the RVA-induced diarrhea and deficient lacta-
tion. Efforts were made at all stages of the experiments to minimize the suffering of animals.
The local Institutional Committee for the Care and Use of Experimental Animals approved the
followed protocol (Comité Institucional para el cuidado y uso de animales de experimenta-
ción–CICUAE- Protocol number 26/2014, CICVyA, INTA-Castelar, Argentina).
Experimental design
In all cases, four-day old pups were used for the experiments. Challenge conditions were previ-
ously standardized to produce diarrhea in 100% of untreated mice. For viral inoculation, pups
received 5 μl of Sodium Bicarbonate (5% w/v), followed by 100 μl of murine ECw RVA (1778
DD50) at PID 0. Viral inoculation and all treatments were administered using a flexible intra-
gastric gauge. All pups were examined daily to assess the occurrence of diarrhea by gentle
abdominal palpation and collection of feces, by a researcher working blinded to the treatment
assignment. Each litter was considered to have diarrhea if at least one pup from the litter pre-
sented soft or aqueous feces. In the present study, we modified previous schedules to analyze
the development of the viral infection at the intestinal tissue and to monitor the evolvement of
the disease until the resolution of the symptoms. In brief, control and treated mice were eutha-
nized sequentially from PID 0 to 6 for prophylactic groups and from PID 0 to 7 for pre-symp-
tomatic and post-symptomatic therapeutic groups (Fig 1). For prophylactic studies, final
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euthanasia was performed at PID 7 whereas for therapeutic groups it was conducted at PID 8
(Fig 1). After sacrifice, sera and intestinal samples were collected. Fecal and intestinal samples
were tested by ELISA to determine viral shedding and intestinal samples were also analyzed by
CCIF to detect infectious RVA particles.
Prophylactic assays. Both VHH, 2KD1 and 3B2, have been tested previously as prophy-
lactics against RVA-associated diarrhea in the neonatal mouse model [26,37]; however, on
those occasions all mice were euthanized at PID 4 and the only dosage used was 100 μg of
VHH. We conducted new tests with a different time frame (Fig 1) and exploring the efficacy of
two higher doses, using four litters of suckling mice for each daily treatment: 160 μg of 2KD1
+3B2 (N = 31) and 200 μg of 2KD1+3B2 (N = 30). In both cases we used equal amounts of
each VHH clone per dose and the treatment started on PID -1 and was administered until PID
6 (Fig 1). On PID 0, the VHH were administered 2 hours prior to viral challenge.
Pre-symptomatic therapeutic assays. Previous studies comprising different therapeutic
treatments of RVA-induced diarrhea in mice started treatment administration between 2 and
24 hours post-infection [5,43,50]. For the therapeutic approach, we first conducted a pilot
assay consisting of a dose/response test where we assessed three doses of treatment: 100 μg of
2KD1+3B2 (50 μg of each), 160 μg of 2KD1+3B2 (80 μg of each), 200 μg of 2KD1+3B2 (100 μg
of each). Given that the lowest dosage (100 μg) did not modify the course of diarrhea and viral
shedding in any way with respect to the untreated control (data not shown), this group was
excluded from further analysis. At PID 0, all mice were inoculated with 1778 DD50 of murine
ECw RVA (Fig 1). In order to study the therapeutic effect of 2KD1 and 3B2 against RVA-
induced diarrhea, we started the treatment at PID 1 so that one cycle of viral replication in vivo
was completed. This approach sought to avoid neutralization of the viral inoculum by VHH
before successful infection was established. From PID 1 to 7, we tested four VHH daily treat-
ments employing four litters of suckling mice for each: 160 μg of 2KD1+3B2 (80 μg of each)
(N = 25), 200 μg of 2KD1+3B2 (100 μg of each) (N = 28), 200 μg of 3B2 (N = 24), 200 μg of
2KD1 (N = 30). Controls included: untreated ECw RVA-inoculated mice (untreated control
group); untreated and not RVA-inoculated mice (normal control group). Anti-RVA murine
Abs were determined by an isotype-specific ELISA in sera and intestinal samples at PID 0, 7
and 40. The occurrence of an immune response against the VHH was determined by measur-
ing the presence of anti-VHH Abs titers at PID 0, 7 and 40 using a murine isotype-specific
ELISA, and sera and intestinal samples of the treated mice as well as the control mice were
tested. Translocation of VHH from the intestinal lumen to the serum of mice was determined
up to PID 7 by an ELISA measuring functional levels of VHH.
Fig 1. Experimental design. The thin horizontal lines represent the duration of the treatment with VHH. On PID 0, all groups were inoculated with
1778 DD50 of murine RVA (ECw). Prophylactic groups received the first daily doses of VHH on PID -1 and on PID 0, two hours before they were
challenged with the viral inoculum. Pre-symptomatic and post-symptomatic treatments began on PID 1 and PID 2. Final euthanasia was performed
at PID 7 for prophylactic groups and at PID 8 for therapeutic pre- and post-symptomatic groups. PID: Post Inoculation Day.
doi:10.1371/journal.pone.0162351.g001
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Post-symptomatic therapeutic assays. Previous results from the standardization of the
neonatal mouse model showed that mice infected with RVA present the first diarrheal symp-
toms at PID 2 (data not shown). If anti-RVA VHH were used to treat pediatric patients suffer-
ing RVA-associated diarrhea, the administration of the VHH would start after the onset of the
first symptoms. In order to determine if post-symptomatic therapeutic treatment (starting at
diarrhea onset, PID 2) with the VHH would achieve similar levels of efficacy than pre-symp-
tomatic treatment (starting at PID 1), an additional group of mice, comprising four litters of
suckling mice (N = 24), was added. Mouse pups were inoculated at PID 0 with 1778 DD50 of
murine ECw RVA as described and received a daily dose of 200 μg of 2KD1 from PID 2 (Fig 1),
at which time all mice in the group had already developed diarrhea, to PID 7. Normal control
group and untreated control group were included.
RVA antigen and virus detection
RVA shedding was detected in feces using an antigen capture ELISA as described previously
[51,52]. Infectious virus titer was assessed by CCIF assay as detailed in previous studies [53].
We used an anti-RVA bovine IgG Ab labeled with FITC and both 2KD1 and 3B2 labeled with
Alexa Fluor (Invitrogen) to reveal RVA-infected cells. Fluorescent cells were counted using a
fluorescence microscope and titers were expressed as the reciprocal of the highest dilution
showing RVA-infected cells.
Murine isotype-specific Ab to ECw RVA ELISA
Anti-RVA IgA and IgG Ab titers were quantified in intestinal contents and sera, respectively.
We decided to detect only the main isotype expected to appear in each kind of tissue, because
of the small amount of sample available. We used an indirect ELISA based on the protocol
described previously [52,54,55] with several modifications. Briefly, 96-well plates (NUNC--
Maxisorp) were coated at 37°C with a pig hyperimmune serum against RVA and blocked with
10% non-fat milk (prepared in PBS-tween 0.5%). Murine ECw RVA (103 FFU/ml) or mock-
infected MA-104 cell supernatant fluids were added for another hour at 37°C. Serial 4-fold
dilutions starting at 1:4 of each sample were assayed, followed by incubation with commercial
Horseradish Peroxidase (HPR) labeled goat polyclonal Ab to murine IgA (1:3000) (KPL) or
HRP-labeled goat polyclonal Abs to murine IgG (1:3000) (KPL) for 1 h at 37°C. Commercial
hydrogen peroxide and ABTS (Sigma-Aldrich) were used as substrate/chromogen system, and
the reaction was stopped with Sodium Dodecyl Sulfate (SDS) 5%. Serum and intestinal con-
tents from two adult mice previously immunized with murine RVA were used as positive con-
trols whereas serum and intestinal contents obtained from naïve mice served as negative
controls for this assay. Optical density measured in mock-coated wells was subtracted from the
one obtained in virus-coated wells and the cut off point for the assay was established as the
mean plus three standard deviations of the corrected optical density measured in virus-coated
PBS wells (blank).
Host humoral immune response against VHH
Anti-VHH IgG and IgA Abs titers were quantified by ELISA in sera and intestinal samples
respectively, of treated mice. We decided to detect only each isotype in the tissue where it rep-
resented the main Ab response, given the small amount of biological samples available. Briefly,
96 well plates (NUNC-Maxisorp) were coated with 50 ng per well of purified monovalent
VHH 2KD1 or 3B2 and then blocked with 10% non-fat milk (in PBS-tween 0.5%). Serial four-
fold dilutions of the samples starting at 1:4 were incubated for one h at 37°C followed by incu-
bation with commercial HRP-labeled goat polyclonal Abs to murine IgG at a 1:3000 dilution
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(KPL) or commercial HPR-labeled goat polyclonal Ab to murine IgA at 1:3000 dilution (KPL).
Commercial hydrogen peroxide and ABTS (Sigma-Aldrich) were used as substrate/chromogen
system. The cut off point for the assay was established as the mean plus three standard devia-
tions of the optical density measured in virus-coated PBS wells (blank). This ELISA was stan-
dardized using mice hyperimmune serum against VHH as positive control and serum samples
from non-immunized mice as negative controls obtained from the experiment described
below.
In order to study the immunogenicity of anti-RVA VHH when these were administered sys-
temically, we performed an additional assay using adult mice. In all cases, mice were immu-
nized subcutaneously twice with 50 ng of either 2KD1 or 3B2 at PID 0 and 21. Four groups,
each comprising four adult mice, were used and received the following treatments: 2KD1 (50
ng); 2KD1 (50 ng) + adjuvants; 3B2 (50 ng); 3B2 (50 ng) + adjuvants. The employed adjuvants
were Freund’s complete adjuvant for the first immunization and Freund’s incomplete adjuvant
for the second one. Blood samples were obtained at PID 30 and 60 and later analyzed for seric
anti-VHH IgG Abs.
Screening of anti-VP6 VHHmurine RVA escape mutants in mice
samples
We analyzed intestinal and fecal samples from mice treated therapeutically with anti-VP6
VHH that were positive for RVA by CCIF or ELISA after 4–6 days of passive treatment admin-
istration. The main goal of this assay was to explore whether these samples contained RVA
VP6 escape mutants, which may had emerged due to the passive treatment. We used viral inoc-
ula and samples from untreated mice as controls. The viral RNA was extracted using the
QIAamp Viral RNAMini Kit (Qiagen) following manufacturer’s instructions from a 200 μl
starting volume of the centrifuged suspensions. The recovered RNA was eluted in 40 μl of elu-
tion buffer and stored at -80°C until further use. The whole encoding gene for VP6 (1356 bp)
was amplified by RT-PCR as described previously [56]. The PCR amplicons were purified
using ExoSAP-IT (Affymetrix USB), and sequenced for both sense/antisense using the dideox-
ynucleotide chain termination method with the ABI PRISM1 BigDye Terminator Cycle
Sequencing Reaction kit (Perkin-Elmer Applied Biosystems) on an automated sequencer (ABI
PRISMTM 3130) from the Sequencing Service, Biotechnology Institute (INTA, Argentina).
Sequences were edited using BioEdit 7.0.9.0 Sequence Alignment Editor [57]. Comparisons
between nucleotide and amino acidic sequences were conducted using MEGA5 [58]. A phylo-
genetic tree was constructed using the Maximum Likelihood method based on the Tamura
3-parameter model using a bootstrap statistical support of 1000 repetitions. Other reference
murine RVA strains were obtained from GenBank.
Proteolytic resistance of anti-VP6 VHH
In order to study the stability and protease resistance of the VHH we conducted two separated
experiments in which we examined stability at low pH and resistance to gastric and intestinal
enzymes for 2KD1 and 3B2, respectively. To study stability and resistance of the VHH in con-
ditions that emulate the host’s stomach, aliquots consisting of 400 μg/ml of 2KD1 or 3B2 were
incubated in Simulated Gastric Fluid (SGF; pH 1.2) with and without enzymes for up to one
hour at 37°C. We also tested the resistance to gastric enzymes in the presence of ORS. The
experiment included the following samples: 3B2+SGF (pH 1.2); 3B2+SGF without enzymes
(pH 1.2); 3B2+SGF+ORS (pH 7.1). The SGF was prepared following the US Pharmacopeia
guidelines, with a final porcine pepsin concentration of 0.32% w/v and pH 1.2. On the other
hand, we examined the VHH’s resistance to intestinal proteases, by incubating 400 μg/ml of
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2KD1 or 3B2 in Simulated Intestinal Fluid (SIF) with or without ORS for up to one hour at
37°C: 2KD1+SIF (pH 6.8); 2KD1+SIF without enzymes (pH 6.8); 2KD1+SIF+ORS (pH 7.1).
The SIF was also prepared following the US Pharmacopeia guidelines, with a final pancreatine
concentration of 1% w/v and pH 6.8. All samples were analyzed by an ELISA that measures
VHH titers against RVA VP6 to determine the remaining percentage of functional VHH, as
was previously described.
Binding affinity and neutralization activity of 2KD1 and 3B2 against RVA
Binding affinity of each VHH clone was studied in a specific ELISA that detects VHHmole-
cules attached to RVA particles. Briefly, 96-well plates (NUNC-Maxisorp) were coated at 37°C
with a specific bovine IgG Ab against RVA (1:5000) and blocked with 10% non-fat milk (pre-
pared in PBS-tween 0.5%). Bovine RVA (UK strain G6P[5]; 103 FFU/ml) or mock-infected
MA-104 cell supernatant fluids were added for another hour at 37°C. Serial five-fold dilutions
were assayed for both clones starting at an initial concentration of 1.78 μg/ml for 3B2 and
7.6 μg/ml for 2KD1. This step was followed by incubation with rabbit hyperimmune serum
against VHH and later with commercial Horseradish Peroxidase (HPR) labeled goat polyclonal
Ab to rabbit IgG (1:2000; KPL) for 1 h at 37°C. Commercial hydrogen peroxide and ABTS
(Sigma-Aldrich) were used as substrate/chromogen system, and the reaction was stopped with
SDS 5%. We used 3B2 and 2KD1 VHH previously produced and characterized as positive con-
trols whereas a non-related VHH was used as negative control for the assay. Optical density
measured in mock-coated wells was subtracted from the one obtained in virus-coated wells
and corrected ODs (at 405 nm) were plotted versus logarithm of the Abs concentration (μg/
mL) and fitted using a sigmoidal dose-response analyses of non-linear data using GraphPad
Prism 7 software. The EC50 (50% effective concentration) values were calculated and used for
quantification and characterization of VHH binding affinity to RVA particles.
In order to provide further evidence regarding anti-RVA neutralization (VN) activity of the
VHH, we conducted a fluorescent focus neutralization (FFN) test as previously described [52].
Given that 3B2 had already been tested by Vega et al. [36] for various human RVA strains, we
determined VN titers of 2KD1 for the same strains. Also, we analyzed VN titers of both clones
against the murine RVA strain used in mice experiments (ECw). Briefly, a four-fold dilution of
each VHH clone (3B2, 2KD1 or a non-related clone) was mixed with an equal volume of RVA
containing 100 DICT. The VN titer was expressed as the reciprocal of the highest sample dilu-
tion that resulted in 80% reduction in the number of fluorescent foci. The 80% reduction crite-
rion was selected in order to be more stringent than in protocols considering only 50%
reduction.
Statistical analysis
Viral and Abs titers were log10 transformed and negative samples were assigned an arbitrary
titer of 2 (log10 = 0.31) for calculations. The Area Under the Curve (AUC) was calculated for
intestinal samples and feces. A one-way fixed effects ANOVA model (parametric) was used to
compare duration of diarrhea and cumulative titers of virus shed in feces and intestines (Area
Under the Curve -AUC- comparison) between treatments and with the untreated control
when previous assumptions of normality and heterogeneity of variances were fulfilled using
Shapiro-Wilks and Levene tests. Kruskal-Wallis rank sum test (non-parametric) was used
when parametric tests’ assumptions were not complied. Proportions of mice with diarrhea for
each day were compared using Fisher’s Exact Test. Differences in anti-RVA Ab titers among
groups were evaluated by comparison of means at three different time-points post virus inocu-
lation (PID 0, 8, 40) using a One-way ANOVA followed by Bonferroni pairwise comparison.
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Statistical significance was assessed at p = 0.05 for all comparisons. Statistical analyses were
conducted using Infostat1 statistical software.
Results
Prophylactic administration of anti-VP6 VHH significantly reduced
diarrhea duration, intestinal RVA infection and RVA shedding in feces
The aim of the present experiment was to evaluate the protection of combined orally adminis-
tered VP6-specific VHH (clones 3B2 and 2KD1) against murine RVA-associated diarrhea in
the neonatal mouse model (Fig 1). At PID 0, all mice were infected with 1778 DD50 of murine
ECw RVA (G16P[16]I7) two hours after VHH treatment. Fig 2 shows the presence of diarrhea
and infectious RVA particles in the intestines of all groups, except for non-inoculated control
mice that did not present viral titers at any time (data not shown). Prophylactic administration
of 2KD1+3B2 VHH significantly delayed the onset of diarrhea, reducing the percentage of
affected mice at PID 2 from 100% in the untreated group to 15% in 160 μg VHHmix/dose
(p<0.0001) and 44% in the 200 μg VHHmix/dose (p<0.0001) (Fig 2). At this experimental
time, the percentage of mice showing diarrhea was significantly higher in 200 μg VHH group
than in the 160 μg VHH one (p = 0.02). However, no further differences were observed from
PID 3 on. Furthermore, diarrhea duration was reduced in all VHH-treated mice to 3.25 days
(160 μg 2KD1+3B2) and 3.5 days (200 μg 2KD1+3B2) compared to 6.75 days in the untreated
control (p = 0.001).
Viral load in the intestinal tissue was also assessed by CCIF assay using samples from
sequential euthanasia (Fig 2). None of the VHH-treated groups displayed detectable RVA
infectious particles in intestinal samples from PID 0 to 5, whereas mice in the untreated group
control showed persisting viral titers from PID 1 on until the end of the experiment. On the
whole, this accounted for a significant reduction in the severity of intestinal infection between
groups receiving the VHH passive treatment and the untreated control (AUC comparison,
p<0.0001). At PID 6, a single peak was observed in 75% (3/4) of the litters from both groups
receiving the passive treatment (Fig 2), which implied no significant difference between them
(p>0.05). No virus shedding was detected by ELISA in the feces from treated mice whereas the
untreated control experienced persisting fecal shedding from PID 2 to 7 (Fig 3).
In order to study whether administration of VHH could modify the Ab responses against
RVA, murine anti-RVA IgG and IgA Abs were evaluated in serum samples and intestinal con-
tents respectively at PID 0, 8 and 40 (Fig 2). All animals from all experimental groups devel-
oped immune responses to RVA during the experiment. At PID 8, mice treated with the
highest dose of VHH (200 μg) showed no detectable anti-RVA IgA titers in intestinal tissue, in
contrast with animals treated with 160 μg VHH and the untreated control group. No signifi-
cant differences were found between the latter two groups (p>0.05) (Fig 2). From PID 8 to 40,
anti-RVA IgA Ab titers rose in all experimental groups, even for animals in 200 μg VHH
group. However, at PID 40 the untreated control group showed an average IgA Ab titer of 1625
whereas mice receiving 160 μg and 200 μg presented average IgA Ab titers of 256 and 141
respectively, which implied a significant reduction when compared to the control (p = 0,001)
(Fig 2). Serum anti-RVA IgG Abs levels showed a similar pattern. At PID 8, mice treated pro-
phylactically with 200 μg of VHH showed one-fold lower Ab titers in serum samples than the
untreated mice (p = 0.006) with an average Ab titer of 9.5 versus 128 in the control group. On
the other hand, mice receiving 160 μg of the passive treatment presented an average IgG Ab
titer of 22, similarly to the results obtained in the control group (p>0.05). At PID 40, both
treated groups showed statistically significant differences with untreated mice (p = 0.002), even
when IgG Ab titers in all groups of animals were higher at this experimental time point than in
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Fig 2. Effect of prophylactic administration of 2KD1+3B2 VHH on RVA-induced diarrhea and host humoral immune response against RVA. All
mice were orally inoculated with 1778 DD50 of ECw RVA at day four of life (PID 0), as indicated by the arrow. Mice were euthanized sequentially to
obtain intestinal tissue (3–4 mice per time point). Graphics on the left side of the panels depict intestinal infectious RVA titers (by CCIF) and diarrhea
prevalence. Blue lines show the development of intestinal RVA disease whereas vertical bars show the mean percentage of mice with diarrhea per
group. The * symbol indicates that the percentage of mice with diarrhea was significantly lower than in the untreated control group (Fisher Exact test).
The thin horizontal line indicates the duration of VHH passive treatment. Graphics on the right side of the panel display humoral immune responses
against RVA. Anti-RVA IgA in intestinal samples and serum IgG Ab titers were determined by ELISA at PIDs 0, 8 and 40. The # and * symbols indicate
that the Ab titers of intestinal IgA and serum IgG, respectively, were significantly lower than the corresponding Ab titers in the untreated control group
(One-way ANOVA). PID: Post Inoculation day.
doi:10.1371/journal.pone.0162351.g002
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all the previous ones: an average IgG Ab titer of 90 and 64 in mice treated with 160 μg and
200 μg of 2KD1+3B2 respectively.
Pre-symptomatic therapeutic administration of anti-VP6 VHH reduced
duration and severity of diarrhea and RVA shedding in feces
Four day-old mouse pups were inoculated with murine ECw RVA strain (G16P[16]I7)–PID 0-
. From PID 1 (24 h post-virus inoculation) to PID 7 included (see Fig 1), four groups of mice
received a daily passive treatment consisting of: 160 μg/dose of 2KD1+3B2 200 μg/dose of
2KD1+3B2, 200 μg/dose of 2KD1 or 200 μg/dose of 3B2. Untreated animals were included as a
control group. Results for diarrhea and intestinal infectious virus titers are depicted in Fig 4. At
PID 2, mice from all experimental groups developed diarrhea. At PID 6, the percentage of mice
with diarrhea significantly decreased in groups receiving 200 μg of 2KD1+3B2 (p = 0.0003),
200 μg of 2KD1 (p = 0.0003) and 200 μg of 3B2 (p = 0.0009) when compared to the untreated
control. By PID 7, none of the mice in these groups showed any signs of diarrhea (Fig 4)show-
ing a significant reduction in diarrhea duration from 6.75 days in the untreated group to an
average of 4.75 days in mice receiving a 200 μg/dose of the VHH (p = 0.002). Overall, no signif-
icant differences were found between groups treated with 200 μg of 2KD1, 3B2 or the 1:1 mix-
ture of both clones (p>0.05). On the other hand, mice treated with 160 μg of the VHHmixture
evidenced a trend to decrease the percentage of mice affected with diarrhea from PID 6
(62.5%) but were not able to significantly reduce diarrhea duration when compared with
untreated animals (p>0.05).
Regarding infectious RVA titers in intestinal samples, mice treated with 160 and 200 μg of
2KD1+3B2 and 200 μg of 2KD1 only showed infectious RVA particles at PID 1. By PID 2,
Fig 3. Effect of prophylactic administration of 2KD1+3B2 VHH on RVA shedding in feces.Mean titer of virus shed
(determined by ELISA) detected daily in pooled feces for mice treated prophylactically with VHH and the untreated control
group. Treated groups did not display detectable fecal shedding at any time. The arrow shows inoculation time (PID 0) and the
thin horizontal line indicates the duration of VHH passive treatment. PID: Post Inoculation Day.
doi:10.1371/journal.pone.0162351.g003
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Fig 4. Effect of pre-symptomatic therapeutic administration of VHH on RVA-induced diarrhea and host humoral
immune response against RVA. All mice were orally inoculated with ECw RVA (1778 DD50) at day four of life (PID 0), as
indicated by the arrow. Mice were euthanized sequentially to obtain intestinal tissue (3–4 mice per time point). Graphics on
the left side of the panel depict intestinal infectious RVA titer and the incidence of diarrhea. Blue lines show the development
of intestinal RVA disease whereas vertical bars show the mean percentage of mice with diarrhea per group. The * symbol
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these treated groups evidenced significantly lower titers when compared to the untreated con-
trol group (p = 0.02), which showed persisting intestinal RVA infection from PID 1 to 6 (Fig
4). On the other hand, mice receiving 200 μg of 3B2 showed conflicting results, as some of the
litters (50%, 2/4) presented sustained RVA infection throughout the treatment, while others
tested negative along the experiment (Fig 4), although RVA titters were lower than in the
untreated control at all times. All treated groups, except for the one receiving 200 μg of 3B2,
significantly diminished the severity of intestinal RVA infection when compared with the
untreated control (AUC comparison, p = 0.04).
Therapeutic use of the VHH also achieved a significant reduction of RVA shedding in feces
in all VHH-treated groups when compared to the untreated group (AUC comparison,
p = 0.01), which showed continuous shedding of viral particles from PID 2 to 6 (Fig 5). Mice
treated with 200 μg of 2KD1+3B2 only displayed viral shedding at PID 1 and 2 whereas mice
receiving 200 μg of 3B2 showed viral shedding at PID 2 and 5–7 (Fig 5). Mice receiving 160 μg
of 2KD1+3B2 presented a higher RVA shedding peak at PID 2 and a lower one at PID 6. Inter-
estingly, mice receiving 200 μg of 2KD1 did not display detectable RVA shedding at any time
(Fig 5).
indicates that the percentage of mice with diarrhea was significantly lower than in the untreated control group (Fisher Exact
test). The thin horizontal purple line indicates the duration of VHH passive treatment. Graphics on the right side of the panel
display mice humoral immune response against RVA. Anti-RVA IgA in intestinal samples and serum IgG Ab titers were
determined by ELISA at PID 0, 8 and 40. The # and * symbols indicate that Ab titers of intestinal IgA and serum IgG were
significantly lower than Ab titers in the untreated control group (One-way ANOVA). PID: Post Inoculation Day.
doi:10.1371/journal.pone.0162351.g004
Fig 5. Effect of pre-symptomatic therapeutic administration of 2KD1+3B2 VHH on RVA shedding in feces.Mean titer of
virus shed (determined by ELISA) detected daily in pooled feces for mice receiving pre-symptomatic therapeutic passive
treatment with VHH and the untreated control group. The arrow shows virus inoculation time (PID 0) and the thin horizontal line
indicates the duration of VHH passive treatment. AUC comparison showed that all VHH-treated groups, except for the ones
receiving 200 μg of 3B2, significantly diminished overall fecal shedding with respect to the untreated control (ANOVA,
p = 0.04). PID: Post Inoculation Day.
doi:10.1371/journal.pone.0162351.g005
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At PID 8, all VHH-treated mice showed similar anti-RVA IgA Abs titers than the untreated
control group in intestinal contents (p>0.05) (Fig 4). Even when IgA Ab titers rose from PID 8
to 40 in all groups, the untreated control showed significantly higher titers than all VHH
treated ones at PID 40 (p = 0.03) (Fig 4). Likewise, at PID 8 all treated groups presented detect-
able titers of serum anti-RVA IgG Abs and no significant differences were detected with respect
to the untreated control group (p>0.05). At PID 40, IgG Abs titers to RVA were significantly
higher in the untreated control group than in mice treated with VHH (p = 0.002). Mice receiv-
ing 160 μg of the VHH presented similar titers at PID 40 than at PID 8.
Post-symptomatic therapeutic treatment of RVA-associated diarrhea
with anti-VP6 VHH significantly decreased the severity of intestinal RVA
infection and shedding in feces
Mice received the first passive treatment dose after the occurrence of diarrhea at PID 2 (Fig 1).
A group of four day-old mice -comprising three litters- was inoculated with murine ECw RVA
strain (G16P[16]I7). Mice received 200 μg of 2KD1 from PID 2 to PID 7 (7-day-long
treatment).
As expected, by the beginning of the passive treatment, all mice had developed diarrheal
symptoms (Fig 6). This situation remained until PID 6, where a marked reduction in diarrhea
was observed in mice treated with 200 μg of 2KD1 compared to the untreated control (Fig 6).
By PID 7, only 16.67% of treated mice presented symptoms against 91.67% in the untreated
control group (p = 0.0008). Although there was a trend towards a decrease in diarrhea duration
and severity in VHH-treated mice, it did not present significant differences with the untreated
control group (p>0.05).
Infectious RVA particles in the intestinal contents were first detected at PID 1 in both
groups (Fig 6). However, mice treated with 200 μg of 2KD1 showed significantly lower viral
titers than the untreated control group by PID 3 (p = 0.006; Fig 6). While untreated mice dis-
played persisting RVA titers until PID 7, animals receiving the VHH passive treatment
showed detectable viral titers only at PID 1–2 and 6. Post-symptomatically treated mice also
achieved a significant reduction of RVA shedding in feces when compared to the untreated
control group (AUC comparison, p = 0.002), presenting detectable viral shedding only at
PID 1–2 (Fig 7).
Host specific humoral immune response against VHH was undetectable
up to 60 days post inoculation
Murine anti-RVA VHH were not detected in treated mice serum throughout the experiment
(data not shown). Anti-VHH IgG (from serum samples) and IgA (from intestinal contents)
Abs were measured at PID 0, 8 and 40 against 2KD1 and 3B2 in separated assays using sam-
ples from mice treated therapeutically with the highest dose (200 μg) of 2KD1, 3B2 and
2KD1+3B2. None of the treated mice presented detectable IgG Abs against VHH in serum
even after seven days of continued administration and up to PID 40 (Fig 8). We could not
detect intestinal IgA Abs against the VHH, suggesting that a local humoral immune response
was not developed either (data not shown). Regarding experiments in which adult mice were
immunized subcutaneously with 2KD1 or 3B2, we found that mice immunized in the pres-
ence of adjuvants showed high titers of seric IgG Abs to the VHH at PID 60 (Fig 8). On the
other hand, mice immunized only with VHH without adjuvants did not develop an immune
response against the VHH, showing no detectable Ab titers against 2KD1/3B2 up to PID 60
(Fig 8).
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RVA escape mutants to the anti-VP6 VHH treatment could not be
detected in vivo
In the prophylactic and therapeutic assays conducted in this work we found intestinal and fecal
samples from VHH-treated mice that tested positive for RVA at PID 5–6 (Fig 2 and Fig 4).
Given that previous samples from these groups were negative for RVA, we aimed to elucidate if
these RVA-positive samples may represent VP6-escape mutants to the passive treatment. A set
of four samples of VHH-treated mice from different groups were further studied: one sample
Fig 6. Effect of post-symptomatic therapeutic administration of VHH on RVA-associated diarrhea in neonatal mice. All mice were orally
inoculated with ECw RVA at day four of life (PID 0), as indicated by the arrow. Mice were euthanized sequentially to obtain intestinal tissue (3–4 mice
per time point). Blue lines depict the development of intestinal RVA disease while vertical bars show the mean percentage of mice with diarrhea per
group. The * symbol indicates that the percentage of mice with diarrhea was significantly lower than in the untreated control group (Fisher Exact test).
The thin horizontal line shows the duration of the passive treatment. PID: Post Inoculation Day.
doi:10.1371/journal.pone.0162351.g006
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from mice treated prophylactically with 160 μg of 2KD1+3B2 (Fig 2) and three samples from
mice treated therapeutically with 200 μg of 3B2 (Fig 4). We also included one sample from
untreated control group and the viral inoculum as negative controls. Analyses of the obtained
VP6 gene sequences showed no nucleotide differences among samples from VHH-treated and
untreated mice (100% nucleotide sequence identity for complete VP6 coding sequence) (data
available upon request). The phylogenetic analysis was consistent and our samples represent a
unique branch that included the viral inoculum, untreated, prophylactic and therapeutic sam-
ples (Fig 9). Finally these samples tested positive by CCIF for RVA using both VHH, 3B2 and
2KD1, labeled with Alexa fluor.
Anti-RVA VHH 3B2 and 2KD1 resisted gastric enzymes in the presence
of ORS
Regarding proteolytic resistance to pepsin present in SGF, both 2KD1 and 3B2 were shown to
be severely degraded by gastric pepsin, with less than 10% of 2KD1 and less than 20% of 3B2
remaining functional after incubation for one hour (Fig 10). On the other hand, we could
determine that the VHH presented high stability at pH 1.2 and that the observed degradation
was only caused by pepsin activity and not by low pH conditions. Interestingly, when both
clones were incubated in SGF in the presence of ORS degradation by pepsin was prevented,
with over 90% of the VHH remaining functional after one hour incubation (Fig 10). On the
other hand, 2KD1 and 3B2 samples incubated with SIF did not show any significant sign of
degradation with around 95% of the VHH remaining functional after one hour incubation
Fig 7. Effect of post-symptomatic therapeutic administration of anti-VP6 VHH on RVA shedding in feces.Mean titer of
virus shed (determined by ELISA) detected daily in pooled feces frommice receiving pre-symptomatic and post-symptomatic
treatment comprising 200 μg of 2KD1 and the untreated control group. The arrow shows inoculation time (PID 0). Post-
symptomatic administration of 2KD1 (200 μg) significantly reduced overall fecal shedding with respect to the untreated control
group when AUC comparison was performed (ANOVA, p = 0.002). The thin horizontal line indicates the duration of VHH
passive treatment. PID: Post Inoculation Day.
doi:10.1371/journal.pone.0162351.g007
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(Fig 10). These results suggest that the critical step for an efficient intestinal delivery of the
VHH would be achieving resistance to gastric pepsin.
Fig 8. Humoral Ab responses against anti-RVA VHH in mice treated with anti-VP6 VHH. The panel
above shows seric IgG Ab response against anti-VP6 VHH in neonatal mice that received oral therapeutic
treatment for seven days, consisting of: 2KD1 (200 μg), 3B2 (200 μg) and 2KD1+3B2 (200 μg). The control
employed for this assay was serum from an adult mice immunized subcutaneously with 2KD1 (50 ng) in the
presence of adjuvants. The panel below shows seric IgG Ab response against 2KD1/3B2 in adult mice
immunized subcutaneously with 50 ng of VHH at PID 0 and 21 with or without adjuvants. For this experiment,
four adult mice per group were used. The adjuvant employed was Freund’s complete adjuvant for the first
immunization, while Freund´s incomplete adjuvant was used in the second one. Arrows indicates
immunization time for both experiments.
doi:10.1371/journal.pone.0162351.g008
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2KD1 showed higher binding affinity to RVA particles than 3B2
The binding affinity to the viral target was three-fold higher for 2KD1 than for 3B2, with EC50
values of 0.0016 μg/ml and 0.0048 μg/ml respectively (Fig 11). Both VHH clones were able to
neutralize a broad range of RVA strains (S1 Table) including worldwide prevalent human RVA
strains such as Wa (G1P[8]I1) and DS1 (G2P[4]I2) and local strain Arg720 (G12P[9]I?). For
some RVA strains, including the murine RVA strain used in mice experiments, 2KD1 seemed
to be more potent than 3B2, as up to four-fold lower concentrations of 2KD1 achieved success-
ful neutralization of viral particles (S1 Table).
Discussion
RVA gastroenteritis remains a major cause of infant morbidity and mortality with 90% of
RVA-associated deaths occurring in low-income settings [59–61]. Previous studies have shown
that administration of anti-RVA VHHmitigated or prevented the occurrence of RVA-induced
diarrhea in the neonatal mouse and the gnotobiotic pig model of RVA infection and disease,
respectively. Anti-RVA VHH were successfully produced in genetically engineered probiotics
(L. paracasei) [46–48] which represents an affordable and efficient treatment strategy that
could minimize concerns about the use of Abs within affected children’s households given cur-
rent widespread of probiotics. Another interesting approach was the expression of anti-RVA
VHH in transgenic rice plants, given that it combined the astringent properties of rice water
against diarrhea together with specific anti-RVA Abs [43]. However, these studies focused only
on the preventive use of VHH against RVA-induced diarrhea.
The main goal of this work was to evaluate the use of two clones of anti-VP6 VHH Abs
-2KD1 and 3B2- in the therapeutic treatment of RVA-induced diarrhea using a neonatal
mouse model infected with a high dose of murine RVA (1778 DD50 of EcW strain). Although
neonatal mice are also susceptible to other strains of RVA until 14 days of life, we chose to use
an homologous RVA because it is more virulent and replicates more efficiently in mouse intes-
tine than heterologous RVA strains [62]. It has been demonstrated in suckling mice that enteric
replication of murine RVA ECw is 1000 to 10,000-fold greater than that of a simian RVA strain
[62]. Previous studies that evaluated other VHH (ARP1) for the treatment of RVA-induced
Fig 9. Phylogenetic analysis of VP6 sequences. The phylogenetic tree was constructed using the
Maximum Likelihood method based on the Tamura 3-parameter model. Bootstrap statistical support (1000
repetitions) is shown. All the used strains are named with the Genbank accession number and strain name.
The experimental samples are indicates as: blue circle = Prophylactic PID 7; red circle = therapeutic PIDs;
black circle = untreated and; white circle = viral inoculum.
doi:10.1371/journal.pone.0162351.g009
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diarrhea employed a neonatal mouse model infected with simian RVA (Rhesus strain, RRV).
More recently, a field trial involving pediatric patients showed that, while ARP1 VHH success-
fully decreased total stool output and rehydration requirements, it failed to reduce the duration
of diarrhea [49], when previous assays in neonatal mice infected with Rhesus RVA had
decreased diarrhea duration among treated animals [44,50]. Despite obvious limitations for
extrapolating results from animal models to field trials involving human patients, these differ-
ences among RVA strains could suggest that the neonatal mouse model infected with a homol-
ogous strain could predict more accurately the efficiency of an anti-RVA treatment in human
patients [63].
Fig 10. Ph stability and proteolytic resistance of anti-VP6 VHH. The graphs show the percentage of remaining functional 2KD1/3B2 after incubation in
SGF (pepsin 0.32% w/v; pH 1.2) or SIF (pancreatin 1%, w/v; pH 6.8) in different conditions, determined by RVA VHH Ab titer ELISA. The panel above
shows pH stability and proteolytic for 2KD1 clone whereas the panel below depicts these parameters for 3B2. In all cases 400 μg of the VHH were
incubated for one hour at 37°C. Experiments were conducted by triplicate. SGF: Simulated Gastric Fluid. SIF: Simulated Intestinal Fluid. ORS: Oral
Rehydration Salts.
doi:10.1371/journal.pone.0162351.g010
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Fig 11. Binding affinity of anti-VP6 VHH to RVA particles.Decreasing concentrations of both 2KD1 and 3B2
were tested for their binding affinity to immobilized RVA particles in an ELISA previously described. Dose-response
curves were fitted using the dose-response sigmoidal model in GraphPad 7 software (available online) obtaining R
square values of 0.990 for 2KD1 and 0.991 for 3B2. The EC50 values were calculated for both clones, showing that
2KD1 had a three-fold higher binding affinity for RVA particles than 3B2: 0.0016 μg/ml vs 0.0048 μg/ml.
doi:10.1371/journal.pone.0162351.g011
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The prophylactic administration of VHH Abs was studied to further understand this
approach in a neonatal mice model followed daily further than PID 4 using a mixture of two
anti-RVA VHH clones (2KD1 and 3B2) to reduce the possibility of emergence of RVA escape
mutants to the treatment. A reduction in the duration of RVA diarrhea that was achieved by
VHH represents the most desirable outcome of any treatment or vaccination, given that even
anti-RVA vaccines do not prevent subsequent infections but mitigate the severity and duration
of the symptoms. Reduction of fecal RVA shedding to undetectable levels is a key feature in
preventing RVA dissemination to naïve individuals. Humoral immune responses to RVA were
detected in all inoculated mice, despite the administration of passive prophylactic treatments,
which are critical to prevent RVA diarrhea after a second exposure to the virus [64,65]. Overall,
the prophylactic administration of anti-VP6 VHHs represents an effective prophylactic strat-
egy against RVA-associated disease and could be used as a complement tool to RVA vaccines
in populations with reduced immunization efficacy.
Post-inoculation treatment with all VHH combinations (2KD1, 3B2, 2KD1+3B2) achieved
a reduction in the duration of diarrhea (in two days) and the severity of the disease. This repre-
sents a promising outcome for a therapeutic treatment against RVA-induced diarrhea adminis-
tered after viral inoculation. The observed persistence of diarrhea after viral clearance could be
explained by the virulence of the murine RVA strain (ECw) used for inoculation. Early studies
using the neonatal mouse model for murine RVA infection reported that once RVA was unde-
tectable at the tissue level, repair of the absorptive cell layers sufficient to restore the normal
transport of fluids across the epithelium facing the gut lumen required more time [66]. It has
been suggested that RVA-associated diarrhea entails a secretory component mediated by
Enteric Nervous System activation and by viral NSP4 [67]. This non-structural protein pays a
role in the regulation of cellular calcium homeostasis and acts as an enterotoxin [67].
Interestingly, the same dose of 3B2 (200 μg) was not able to significantly diminish the sever-
ity of RVA infection in intestinal tissue and showed persisting lower infection titers throughout
the experiment. This may indicate that the administration of 2KD1 alone represents the treat-
ment of choice given that it was also capable of reducing RVA shedding in feces to undetectable
levels. These findings are in accordance with previous studies showing that 2KD1 had a deeper
impact on fecal shedding than 3B2 [37] and with binding affinity experiments conducted in
this work. Clone 2KD1 showed a three-fold higher binding affinity (EC50) to RVA particles
than 3B2 which could explain, at least partly, the higher efficacy in treating RVA-induced diar-
rhea. Also, 2KD1 was able to neutralize some RVA strains more effectively than 3B2, including
murine RVA ECw strain used in mice experiments, which could also explain the better perfor-
mance of 2KD1 observed in this study. Future studies will focus on determining the exact epi-
topes of VP6 to which 2KD1 and 3B2 bind and the affinity of these attachments using Surface
Plasmon Resonance (SPR) equipment.
Given that administration of 2KD1 (200 μg) attained the best results in the pre-symptomatic
treatment of RVA-induced diarrhea, we selected this treatment for a final experiment involving
a post-symptomatic approach. In this case, VHH treatment started on PID 2, at which time all
mice had developed diarrhea. Post-symptomatic therapeutic administration of 2KD1 achieved
a reduction in the severity of intestinal infection and fecal RVA shedding. It also showed a
trend towards the reduction of the percentage of mice with diarrhea by the end of the experi-
ment. These results show that administration of anti-VP6 VHH successfully mitigates RVA
infection, even after the onset of the symptoms, a scenario that emulates more accurately the
potential use of the VHH in pediatric patients.
There are two critical factors regarding any passive Ab therapy: one is the development of a
host immune response to the treatment, especially for heterologous Abs, while the other is the
appearance of virus escape mutants. VHH-treated mice did not develop detectable humoral Ab
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responses against the passive VHH treatment (in sera or intestinal samples) by the methodol-
ogy used. Furthermore, we could not detect translocation of either VHH clone to peripheral
blood. In addition, adult mice vaccinated subcutaneously with VHH without any adjuvants
failed to develop an immune response at least up to 60 days post-immunization whereas mice
vaccinated in the presence of Freund’s complete and incomplete adjuvants presented high titers
of anti-VHH serum IgG. These results suggest that 2KD1 and 3B2 do not show immunogenic
properties on their own for as long as 60 days post administration even when delivered by a
systemic route. This supports that oral VHH administration should not represent a hazard for
pediatric patients.
On the other hand, we studied candidate samples in the search of RVA escape mutants to
VHH in vivo. However, no such mutants were detected by the methodology used. The presence
of viral particles in VHH-treated mice at PID 5–6 may represent a delay in virus replication
due to the passive treatment that is soon controlled by the host local Ab immune response. As
mentioned above, VP6 protein is highly conserved in different RVA strains and this may
explain the absence of escape mutants. However, it is important to consider that the observa-
tion period after VHH treatment was not long enough to reach any decisive conclusions on
this matter. Also, the fact that the VP6 epitope to which the VHH bind has not been elucidated
also hinders the detection of possible RVA escape mutants. Further studies on this matter
should include structural virology analyses of VHH-RVA particles interaction, in vitro passages
of RVA in the presence of large concentrations of VHH and deep sequencing analyses of
potential viral escape mutants.
In this study, we described pre- and post-symptomatic therapeutic treatment of RVA-
induced diarrhea by oral administration of anti-VP6 VHH with broad neutralizing activity
against several RVA strains circulating globally in humans and animals in the neonatal mouse
infected with a murine RVA strain. One of the main challenges of orally administered Abs is
avoiding degradation by gastric enzymes and resisting low pH conditions. Although incubation
of 2KD1 and 3B2 with SGF showed high degradation of the VHH by gastric pepsin, addition of
ORS enhanced the proteolytic resistance of the VHH. Given that ORS are regularly adminis-
tered to RVA-infected children, this could be an affordable and efficient delivery of the treat-
ment in low income settings where it could even be provided as lyophilized powder which
avoiding the need of maintaining cold chains. Given that RVA-associated symptoms some-
times include severe vomiting, it remains a critical aspect for an oral therapy for this disease
how these symptoms could affect an efficient delivery of the treatment to the intestine. The
absence of vomiting reflex in most animal models impairs to take this factor into account in
pre-clinical assays.
This study represents a proof of principle of the efficacy of VHH oral therapy to treat RVA
diarrhea, increasing the understanding of these valuable Abs. We have addressed the possible
emergence of RVA VP6 escape mutants against VHH treatment in vivo (although over a short
observation period) and the potential development of a host humoral immune response against
the passive treatment. Overall, oral therapy using anti-VP6 VHH has enormous potential to be
implemented in developing countries, where RVA mortality is still high and current vaccines
seem less efficacious, and also to be administered to prematurely born or immunedeficient chil-
dren worldwide.
Supporting Information
S1 Fig. SDS-PAGE stained with Coomassie Blue that shows the electrophoretic profile of
VHH production. Lane 1: 2KD1 (after purification); lane 2: 2KD1 (periplasmic extract); lane
3: 2KD1 control; lane 4: 3B2 (after purification); lane 5: 3B2 (periplasmic extract); 3B2 control.
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Control VHH were obtained from previous productions.
(TIF)
S1 Table. In vitro RVA fluorescent focus reduction assay using anti-VP6 VHH. A fourfold
dilution of each VHH clone (2KD1, 3B2 or non-related VHH) was mixed with an equal vol-
ume of RVA containing 100 focus forming units (FFU) of each strain. The numbers represent
the minimum VHH concentration that reduced 80% of the number of fluorescent focus form-
ing units (FFU) of each RVA strain. Neg = no neutralizing activity was observed at the highest
concentration tested (62.5 μg VHH/ml). Nd = not determined. # Results obtained from Garai-
coechea et al., 2008 [37].  Results extracted from Vega et al., 2013 [36]
(DOCX)
Acknowledgments
We would like to thank Dr. Ulrich Desselberger for his kind help with the manuscript and his
valuable suggestions. We are very grateful for the technical assistance of Fátima Torales for car-
ing for the animals and Dr. Marina Bok and M.Sci. Josefina Baztarrica for useful assistance
throughout the experimental procedures. We would also like to thank Dr. Osvaldo Zábal and
Diego Compaired for technical support. We are thankful to Dr. Alejandro Castello for provid-
ing ECw RVA strains used in this work. VP, CGV and LLG are members of CONICET Scien-
tist Carrier, Argentina. LM has a PhD scholarship from CONICET, Argentina.
Author Contributions
Conceptualization: LM CGV VP LG.
Data curation: LM CGV VP LG.
Formal analysis: LM CGV VP.
Funding acquisition: VP.
Investigation: LM CGV LG SM VP.




Validation: LM CGV VP.
Visualization: LM CGV VP.
Writing – original draft: LM CGV VP LG.
Writing – review & editing: LM CGV VP LG SM.
References
1. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. Global, Regional, and National Estimates of Rotavi-
rus Mortality in Children <5 Years of Age, 2000–2013. Clin Infect Dis. 2016; 62: S96–S105. doi: 10.
1093/cid/civ1013 PMID: 27059362
2. WHO- UNICEF, Johns Hopkins School of Public Health U. Implementing the New Recommendations
on the Clinical Management of Diarrhoea Guidelines for Policy Makers and ProgrammeManagers.
Anti-VP6 VHH for Rotavirus A
PLOSONE | DOI:10.1371/journal.pone.0162351 September 7, 2016 23 / 27
World Health Organization, Department of Child and Adolescent Health and Development, and United
Nations Children’s Fund, Programme Division; 2006.
3. Grandy G, Medina M, Soria R, Terán CG, Araya M. Probiotics in the treatment of acute rotavirus diar-
rhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian
children. BMC Infect Dis. 2010; 10: 253. doi: 10.1186/1471-2334-10-253 PMID: 20735858
4. Preidis GA, Saulnier DM, Blutt SE, Mistretta T, Riehle KP, Major AM, et al. Host response to probiotics
determined by nutritional status of rotavirus-infected neonatal mice. J Pediatr Gastroenterol Nutr. 2012;
55: 299–307. doi: 10.1097/MPG.0b013e31824d2548 PMID: 22343914
5. Zhang Z, Xiang Y, Li N, Wang B, Ai H, Wang X, et al. Protective effects of Lactobacillus rhamnosus GG
against human rotavirus-induced diarrhoea in a neonatal mouse model. Pathog Dis. 2013; 67: 184–91.
doi: 10.1111/2049-632X.12030 PMID: 23620181
6. Teran CG, Teran-Escalera CN, Villarroel P. Nitazoxanide vs. probiotics for the treatment of acute rotavi-
rus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int J Infect Dis.
2009; 13: 518–23. doi: 10.1016/j.ijid.2008.09.014 PMID: 19070525
7. Mrukowicz J, Szajewska H, Vesikari T, Mrukowicz ÃJ. Options for the prevention of rotavirus disease
other than vaccination. J Pediatr Gastroenterol Nutr. 2008; 46 Suppl 2: S32–S37. doi: 10.1097/MPG.
0b013e31816f79b0 PMID: 18460970
8. Bae E, Han M, Lee M, Kim D. 2000. In vitro inhibitory effect of some flavonoids on rotavirus infectivity.
Biol Pharm Bull. 2000; 23: 1122–24. PMID: 10993220
9. Kim D, Song M, Bae E, Han M. Inhibitory effect of herbal medicines on rotavirus infectivity. Biol Pharm
Bull. 2000; 23: 356–58. PMID: 10726895
10. Mrukowicz J, Szajewska H, Vesikari T, Mrukowicz ÃJ. Options for the prevention of rotavirus disease
other than vaccination. J Pediatr Gastroenterol Nutr. 2008; 46 Suppl 2: S32–S37. doi: 10.1097/MPG.
0b013e31816f79b0 PMID: 18460970
11. Sarker SA, Casswall TH, Mahalanabis D, Alam N, Albert M, Brüssow H, et al. Successful treatment of
rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum. Pediatr Infect Dis
J. 1998; 17: 49–54.
12. Sarker SA, Casswall TH, Juneja LR, Hoq E, Hossain I, Fuchs GJ, et al. Randomized, placebo-con-
trolled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diar-
rhea. J Pediatr Gastroenterol Nutr. 2001; 32: 19–25. Available: http://www.ncbi.nlm.nih.gov/pubmed/
11176319 PMID: 11176319
13. Sarker SA, Pant N, Juneja LR, Hammarström L. Successful Treatment of Rotavirus-induced Diarrhoea
in Suckling Mice with Egg Yolk Immunoglobulin. J Heal Popul Nutr. 2007; 25: 465–68.
14. Vega CG, Bok M, Vlasova AN, Chattha KS, Fernández FM, Wigdorovitz A, et al. IgY antibodies protect
against human Rotavirus induced diarrhea in the neonatal gnotobiotic piglet disease model. PLoS One.
2012; 7: e42788. doi: 10.1371/journal.pone.0042788 PMID: 22880110
15. Matsui S, Offit P, Vo P, Mackow E, Benfield D, Shaw RD, et al. Passive protection against rotavirus-
induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the
VP8 fragment of VP4. J Clin Microbiol. 1989; 27: 780–782. PMID: 2470774
16. Offit PA, Shaw RD, Greenberg HB. Passive protection against rotavirus-induced diarrhea by monoclo-
nal antibodies to surface proteins vp3 and vp7. J Virol. 1986; 58: 700–703. PMID: 2422398
17. Inagaki M, Yamamoto M, Uchida K, Yamaguchi H, Kawasaki M, Yamashita K, et al. In Vitro and in Vivo
Evaluation of the Efficacy of Bovine Colostrum against Human Rotavirus Infection. Biosci Biotechnol
Biochem. 2010; 74: 680–682. doi: 10.1271/bbb.90862 PMID: 20208370
18. Mine Y, Kovacs-Nolan J. Chicken egg yolk antibodies as therapeutics in enteric infectious disease: a
review. J Med Food. 2002; 5: 159–169. doi: 10.1089/10966200260398198 PMID: 12495588
19. Vega C, Bok M, Chacana P, Saif L, Fernandez F, Parreño V. Egg yolk IgY: protection against rotavirus
induced diarrhea and modulatory effect on the systemic and mucosal antibody responses in newborn
calves. Vet Immunol Immunopathol. 2011; 142: 156–69. doi: 10.1016/j.vetimm.2011.05.003 PMID:
21652087
20. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv
Drug Deliv Rev. 2006; 58: 686–706. doi: 10.1016/j.addr.2006.03.011 PMID: 16839640
21. Reilly R, Domingol R, Sandhu J. Oral Delivery of Antibodies Future Pharmacokinetic Trends. Clin Phar-
macokinet. 1997; 32: 313–323. PMID: 9113439
22. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E, et al. Naturally
occurring antibodies devoid of light chains. Nature. 1993; 363: 446–48. PMID: 8502296
23. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain anti-
body fragments. Appl Microbiol Biotechnol. 2007; 77: 13–22. doi: 10.1007/s00253-007-1142-2 PMID:
17704915
Anti-VP6 VHH for Rotavirus A
PLOSONE | DOI:10.1371/journal.pone.0162351 September 7, 2016 24 / 27
24. Frenken L, van der Linden R, Hermans P, Wil Bos J, Ruuls R, de Geus B, et al. Isolation of antigen spe-
cific Llama V HH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Bio-
technol. 2000; 78: 11–21. PMID: 10702907
25. Arbabi-ghahroudi M, Tanha J, Mackenzie R. Prokaryotic expression of antibodies and affibodies.pdf.
2005; 501–519.
26. Gómez-Sebastián S, Nuñez MC, Garaicoechea L, Alvarado C, Mozgovoj M, Lasa R, et al. Rotavirus A-
specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo.
BMC Biotechnol. 2012; 12: 59. doi: 10.1186/1472-6750-12-59 PMID: 22953695
27. Ismaili A, Jalali-Javaran M, Rasaee MJ, Rahbarizadeh F, Forouzandeh-MoghadamM, Memari HR.
Production and characterization of anti-(mucin MUC1) single-domain antibody in tobacco (Nicotiana
tabacum cultivar Xanthi). Biotechnol Appl Biochem. 2007; 47: 11–9. doi: 10.1042/BA20060071 PMID:
17073735
28. Lentz EM, Garaicoechea L, Alfano EF, Parre??o V, Wigdorovitz A, Bravo-Almonacid FF. Translational
fusion and redirection to thylakoid lumen as strategies to improve the accumulation of a camelid anti-
body fragment in transplastomic tobacco. Planta. 2012; 236: 703–714. doi: 10.1007/s00425-012-1642-
x PMID: 22526499
29. Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013; 82: 775–
97. doi: 10.1146/annurev-biochem-063011-092449 PMID: 23495938
30. Estes MK. Rotavirus and their replication. In: Fields DMKBN, Howley PM, editors. Field’s Virology. Phil-
adelphia: Lippincott—Raven; 2001. pp. 1347–1353.
31. Ward R. Mechanisms of protection against rotavirus infection and disease. Pediatr Infect Dis J. 2009;
28: S57–9. doi: 10.1097/INF.0b013e3181967c16 PMID: 19252425
32. Vanlandschoot P, Stortelers C, Beirnaert E, Ibáñez LI, Schepens B, Depla E, et al. Nanobodies1: New
ammunition to battle viruses. Antiviral Res. 2011; 92: 389–407. doi: 10.1016/j.antiviral.2011.09.002
PMID: 21939690
33. Svensson L, Sheshberadaran H, Vesikari T, Norrby E, Wadell G. Immune response to rotavirus poly-
peptides after vaccination with heterologous rotavirus vaccines (RIT 4237, RRV-1). J Gen Virol. 1987;
68: 1993–1999. doi: 10.1099/0022-1317-68-7-1993 PMID: 3037019
34. Burns JW, Siadat-pajouh M, Krishnaney AA, Greenberg HB. Protective Effect of Rotavirus VP6-Spe-
cific IgA Monoclonal Antibodies That Lack Neutralizing Activity. Science (80-). 1996; 272: 104–7.
PMID: 8600516
35. Corthésy B, Benureau Y, Perrier C, Fourgeux C, Parez N, Greenberg H, et al. Rotavirus anti-VP6
secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune
exclusion. J Virol. 2006; 80: 10692–10699. doi: 10.1128/JVI.00927-06 PMID: 16956954
36. Vega CG, Bok M, Vlasova AN, Chattha KS, Gómez-Sebastián S, Nuñez C, et al. Recombinant mono-
valent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets
against human rotavirus-induced diarrhea. PLoS Pathog. 2013; 9: e1003334. doi: 10.1371/journal.
ppat.1003334 PMID: 23658521
37. Garaicoechea L, Olichon A, Marcoppido G, Wigdorovitz A, Mozgovoj M, Saif L, et al. Llama-derived sin-
gle-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in
vitro and confer protection against diarrhea in mice. J Virol. 2008; 82: 9753–64. doi: 10.1128/JVI.
00436-08 PMID: 18632867
38. van Der Linden RH, Frenken LG, de Geus B, HarmsenMM, Ruuls RC, Stok W, et al. Comparison of
physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Bio-
chim Biophys Acta. 1999; 1431: 37–46. doi: 10.1016/S0167-4838(99)00030-8 PMID: 10209277
39. Dumoulin M, Conrath K, Meirhaeghe AVAN, Meersman F, Heremans K, Frenken LGJ, et al. Single-
domain antibody fragments with high conformational stability. Protein Sci. 2002; 11: 500–15. doi: 10.
1110/ps.34602.500 PMID: 11847273
40. Pellis M, Pardon E, Zolghadr K, Rothbauer U, Vinvke C, Kinne J, et al. A bacterial-two-hybrid selection
system for one-step isolation of intracellularly functional Nanobodies. Arch Biochem Biophys. 2012;
526: 114–123. doi: 10.1016/j.abb.2012.04.023 PMID: 22583807
41. Dolk E, Van Der Vaart M, Hulsik DL, Vriend G, De Haard H, Spinelli S, et al. Isolation of llama antibody
fragments for prevention of dandruff by phage display in shampoo. Appl Environ Microbiol. 2005; 71:
442–450. doi: 10.1128/AEM.71.1.442–450.2005 PMID: 15640220
42. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of
single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. Federation of Euro-
pean Biochemical Societies; 1997; 414: 521–526. doi: 10.1016/S0014-5793(97)01062-4
Anti-VP6 VHH for Rotavirus A
PLOSONE | DOI:10.1371/journal.pone.0162351 September 7, 2016 25 / 27
43. Tokuhara D, Álvarez B, Mejima M, Hiroiwa T, Takahashi Y, Kurokawa S, et al. Rice-based oral antibody
fragment prophylaxis and therapy against rotavirus infection. J Clin Invest. 2013; 123: 3829–38. doi:
10.1172/JCI70266.are PMID: 23925294
44. van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, Bellamy K, et al. Reduction in morbid-
ity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody frag-
ments. Vaccine. 2006; 24: 4130–7. doi: 10.1016/j.vaccine.2006.02.045 PMID: 16616802
45. Aladin F, Einerhand AWC, Bouma J, Bezemer S, Hermans P, Wolvers D, et al. In vitro neutralisation of
rotavirus infection by two broadly specific recombinant monovalent llama-derived antibody fragments.
PLoS One. 2012; 7: 329–49. doi: 10.1371/journal.pone.0032949
46. Pant N, Hultberg A, Zhao Y, Svensson L, Pan-HammarstromQ, Johansen K, et al. Lactobacilli express-
ing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against
rotavirus-induced diarrhea. J Infect Dis. 2006; 194: 1580–8. doi: 10.1086/508747 PMID: 17083044
47. Pant N, Marcotte H, Brüssow H, Svensson L, Hammarström L. Effective prophylaxis against rotavirus
diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. BMCMicrobiol. 2007; 7:
86. doi: 10.1186/1471-2180-7-86 PMID: 17900343
48. Günaydın G, Alvarez B, Lin Y, Hammarström L, Marcotte H. Co-expression of anti-rotavirus proteins
(llama VHH antibody fragments) in Lactobacillus: development and functionality of vectors containing
two expression cassettes in tandem. PLoS One. 2014; 9: e96409. doi: 10.1371/journal.pone.0096409
PMID: 24781086
49. Sarker SA, Jäkel M, Sultana S, Alam NH, Bardhan PK, Chisti MJ, et al. Anti-rotavirus protein reduces
stool output in infants with diarrhea: a randomized placebo-controlled trial. Gastroenterology. Elsevier
Ltd; 2013; 145: 740–48. doi: 10.1053/j.gastro.2013.06.053 PMID: 23831050
50. Pant N, Marcotte H, Hermans P, Bezemer S, Frenken L, Johansen K. Lactobacilli producing bispecific
llama-derived anti-rotavirus proteins in vivo for rotavirus-induced diarrhea. Future Microbiol. 2011; 6:
583–93. doi: 10.2217/fmb.11.32 PMID: 21585264
51. Cornaglia E, Barrandeguy M, Fijtman N, Schudel A. Enzyme linked immunosorbent assay, immunoflu-
orescent test and electrophoresis analysis of rotaviral RNA in the diagnosis and characterization of the
bovine rotavirus. Rev LatinoamMicrobiol. 1989; 59–62.
52. Parreno V, Hodgins DC, De Arriba L, Kang SY, Yuan L, Ward L a., et al. Serum and intestinal isotype
antibody response to Wa human rotavirus in gnotobiotic pigs are modulated by maternal antibodies. J
Gen Virol. 1999; 80: 1417–1428. PMID: 10374959
53. Saif L, Yuan L, Ward L, To T. Comparative studies of the pathogenesis, antibody immune responses
and homologous protection to porcine and human rotaviruses in gnotobiotic piglets. In: Springer US,
editor. Mechanisms in the Pathogenesis of Enteric Diseases. 1997. pp. 397–403.
54. Hodgins DC, Kang SY, deArriba L, Parreño V, Ward L a, Yuan L, et al. Effects of maternal antibodies
on protection and development of antibody responses to human rotavirus in gnotobiotic pigs. J Virol.
1999; 73: 186–197. PMID: 9847321
55. Yuan L, Ward LA, Rosen BI, To TL, Saif LJ, Irol J V. Systemic and Intestinal Antibody-Secreting Cell
Responses and Correlates of Protective Immunity to Human Rotavirus in a Gnotobiotic Pig Model of
Disease †. 1996; 70: 3075–83.
56. Miño S, Matthijnssens J, Badaracco A, Garaicoechea L, Zeller M, Heylen E, et al. Equine G3P[3] rotavi-
rus strain E3198 related to simian RRV and feline/canine-like rotaviruses based on complete genome
analyses. Vet Microbiol. 2013; 161: 239–246. doi: 10.1016/j.vetmic.2012.07.033 PMID: 22959604
57. Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows
95/98/NT [Internet]. Nucleic Acids Symposium Series. 1999. pp. 95–98. citeulike-article-id:691774
58. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: Molecular Evolutionary
Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Meth-
ods. 2011; 28: 2731–2739. doi: 10.1093/molbev/msr121 PMID: 21546353
59. Parashar U, Nelson E. Diagnosis, management, and prevention of rotavirus gastroenteritis in children.
Bmj. 2013; 347: 1–10. doi: 10.1136/bmj.f7204
60. Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE. Global causes of diar-
rheal disease mortality in children <5 years of age: a systematic review. PLoS One. 2013; 8: e72788.
doi: 10.1371/journal.pone.0072788 PMID: 24023773
61. Tate J, Burton AH, Boschi-Pinto C, Duncan Steele A, Duque J, Parashar UD. 2008 estimate of world-
wide rotavirus-associated mortality in children younger than 5 years before the introduction of universal
rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2008; 12:
136–41.
Anti-VP6 VHH for Rotavirus A
PLOSONE | DOI:10.1371/journal.pone.0162351 September 7, 2016 26 / 27
62. Feng N, Yasukawa LL, Sen A, Greenberg HB. Permissive replication of homologous murine rotavirus
in the mouse intestine is primarily regulated by VP4 and NSP1. J Virol. 2013; 87: 8307–16. doi: 10.
1128/JVI.00619-13 PMID: 23698306
63. Maffey L, Vega C, Parreño V, Garaicoechea L. Controlling Rotavirus-associated diarrhea: could Sin-
gle-domain antibody fragments make the difference? Rev Argent Microbiol. 2015; 47: 368–379. doi: 10.
1016/j.ram.2015.09.005 PMID: 26654700
64. Coulson BS, Grimwood K, Masendycz PJ, Lund JS, Mermelstein N, Bishop RF, et al. Comparison of
Rotavirus Immunoglobulin A Coproconversion with Other Indices of Rotavirus Infection in a Longitudi-
nal Study in Childhood. J Clin Microbiol. 1990; 28: 1367–1374. PMID: 2166082
65. Vesikari T, Isolauri E, Delem A, D’Hondt E, Andre FE, Beards GM, et al. Clinical efficacy of the RIT
4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J
Pediatr. 1985; 107: 189–194. PMID: 3894608
66. Little L, Shadduck J. Pathogenesis of Rotavirus Infection in Mice. Inffect Immun. 1982; 38: 755–763.
67. Greenberg HB, Estes MK. Rotaviruses: From Pathogenesis to Vaccination. Gastroenterology. 2009;
136: 1939–1951. doi: 10.1053/j.gastro.2009.02.076 PMID: 19457420
Anti-VP6 VHH for Rotavirus A
PLOSONE | DOI:10.1371/journal.pone.0162351 September 7, 2016 27 / 27
